Organisation paid for research Program year 2025 Source: CMS Open Payments

Biostorage Technologies, Incorporated

Neither a doctor nor a teaching hospital

Research payments

$99,371

55 payments

Through program year 2025, Biostorage Technologies, Incorporated is reported as receiving $99,371 in research payments, across 55 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$5,127	5
2024	Research	$18,468	19
2023	Research	$69,528	25
2022	Research	$6,248	6

Breakdown

Who paid Research payments · program years 2022–2025

E.R. Squibb & Sons, L.L.C. $88,858 48 payments
Celgene Corporation $10,512 7 payments

Studies the money was for Research payments · program years 2022–2025

Phase IIB in HCV SVR (F3/ F4) - A Randomized, Double-Blind, Placebo-Controlled, 2-Part, Parallel Group, Multiple Dose Phase 2 Study To Evaluate The Efficacy and Safety of BMS-986263 In Adults With Advanced Hepatic Fibrosis From Hepatitis C Who Have Achiev $27,866 2 payments
Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in US Community Oncology Practices $10,370 2 payments
SAD MAD Combo - A First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of BMS-986209 in Healthy Participants $9,964 1 payment
A Study to Evaluate the Metabolism and Excretion of [14C]-CC-92480 in Healthy Male Participants $5,969 3 payments
Activated Charcoal Study $3,412 2 payments
DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection $3,410 1 payment
A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986447 in Healthy Participants $3,278 1 payment
A Study to Evaluate the Metabolism and Excretion of BMS-986369 in Healthy Male Participants $3,057 1 payment
Ph1 mCRPC (CC-90011-PCA-001) - A phase 1, open-label, functional imaging study to assess whether CC-90011 reverses the castration resistance due to lineage switch in participants with metastatic castration-resistant prostate cancer (mCRPC) who have failed $2,043 1 payment
MAD in Japanese - A Double-blind, Placebo-controlled, Randomized, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BMS-986322 in Healthy Participants of Japanese Descent $2,037 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.